Abstract
The majority of patients with terminal breast cancer show signs of bone metastasis, the most common cause of pain in cancer. Clinically available drug treatment options for the relief of cancer-associated bone pain are limited due to either inadequate pain relief and/or dose-limiting side-effects. One of the major hurdles in understanding the mechanism by which breast cancer causes pain after metastasis to the bones is the lack of suitable preclinical models. Until the late twentieth century, all animal models of cancer induced bone pain involved systemic injection of cancer cells into animals, which caused severe deterioration of animal health due to widespread metastasis. In this mini-review we have discussed details of a recently developed and highly efficient preclinical model of breast cancer induced bone pain: Walker 256 cancer cell- induced bone pain in rats. The model involves direct localized injection of cancer cells into a single tibia in rats, which avoids widespread metastasis of cancer cells and hence animals maintain good health throughout the experimental period. This model closely mimics the human pathophysiology of breast cancer induced bone pain and has great potential to aid in the process of drug discovery for treating this intractable pain condition.
Introduction
The most common cause of pain in cancer arises from bone metastasis, and around 73% of patients with terminal breast cancer exhibit indications of bone metastases (Coleman, 2006; Currie et al., 2013; Bu et al., 2014). Of these, 75% suffer severe bone pain and pathological fractures (Ibrahim et al., 2013). This is in contrast to primary breast tumors in the tissue of origin that cause very little or no pain at all (Lozano-Ondoua et al., 2013). Clinically, nonsteroidal anti-inflammatory drugs are the mainstay of treatment, often in combination with strong opioid analgesics, radiotherapy in the initial stages of metastasis, and adjuvant agents that inhibit osteoclast activity such as bisphosphonates and denosumab (Mantyh et al., 2002; Colvin and Fallon, 2008; Fallon et al., 2016; Fernandes et al., 2016). The principal challenge in understanding the pathophysiological mechanisms of cancer-induced bone pain (CIBP) is the development of an animal model which has characteristics in common with that of human CIBP (Slosky et al., 2015). It is only recently that preclinical studies have begun to determine how metastatic cancers may interact with the bone microenvironment resulting in pain (Lozano-Ondoua et al., 2013). Until the late twentieth century, all animal models of CIBP relied on systemic injection of carcinoma cells, which resulted in poor animal health because of metastases in vital organs such as the liver, lungs, brain, and multiple sites in bone (Urch, 2004; Simmons et al., 2015). Subsequently, the more efficient method of local infusion of cancer cells into a single bone was developed, thereby avoiding systemic spread of cancer cells and the maintenance of good general animal health (Schwei et al., 1999). Although, multiple breast cancer cell lines have been used to induce bone tumors in rats and mice, the focus of this mini-review is confined to research in which Walker 256 rat breast cancer cells have been used to induce bone pain in rats.
Rat as the species of choice
Rats and mice are the most commonly used animal species for pain research (Walker et al., 1999), with rats being superior to mice in many practical respects (Wilson and Mogil, 2001; Mogil, 2009). The advantage of mouse pain models is the availability of transgenic mice for dissecting pathophysiological mechanisms (Mogil and Grisel, 1998) and mouse models of breast cancer might recapitulate key aspects of human breast cancer including poor immunogenicity and high metastatic potential (Hahn et al., 2006). However, the main disadvantage of mice is their small size, making direct injection of tumor cells into the bone technically challenging (Pacharinsak and Beitz, 2008). By contrast, rat models are considered very suitable for efficacy assessment of therapeutic interventions for the treatment of breast CIBP (Medhurst et al., 2002). The model using Walker 256 cells can be induced in both sexes of rats (Liu et al., 2010, 2011) and different rat strains are compatible with these cells (Earle, 1935; Jensen and Muntzing, 1970). Stage of the estrous cycle in female rats does not alter the development of CIBP (Zhu G. Q. et al., 2014).
Suitability of walker 256 cells
The Walker tumor was first discovered in the breast of a pregnant albino rat (Rattus norvegicus) in 1928 by Dr. George Walker in Baltimore and it is regarded as a carcinosarcoma (McEuen and Thomson, 1933; Simpkins et al., 1991). It is one of the most widely used transplantable tumors in experimental research (Justice, 1985; Brigatte et al., 2007; Fan et al., 2016; Gambeta et al., 2016; Gao et al., 2016; Sroka et al., 2016; Wu M. et al., 2016). Indeed, these cells are one of the most preferred cell lines because of the ease with which they can be standardized, maintained and propagated in vitro, as well as their extensive use in vivo since 1937 (Michaelson and Orcutt, 1957; Brigatte et al., 2016; Galuppo et al., 2016; Pigatto et al., 2016; Trashkov et al., 2016; Yalovenko et al., 2016).
Walker 256 cells cause significant bone resorption and increase skeletal fragility at the site of implantation in rats (Kurth et al., 2000), consistent with the phenotype observed in breast cancer patients with bone metastasis (Shih et al., 2004). In addition to being a reproducible method for inducing skeletal metastasis (Blouin et al., 2005; Mao-Ying et al., 2006; Badraoui et al., 2009), this model mimics key features of human breast CIBP, including pharmacological profile (Mao-Ying et al., 2006, 2012; Cao et al., 2010). Walker 256 cells can be used in a variety of rat strains (Hang et al., 2015; Lu et al., 2015) because these cells produce uniformly rapid growth, show very little regression, and are readily adaptable (Lewis et al., 2013; Oliveira and Gomes-Marcondes, 2016).
Growth of Walker 256 cells in the form of tumor is practically independent of the age and weight of the animals at the time of their inoculation (Walpole, 1951). Another advantage is that after unilateral intra-tibial injection (ITI), tumor cells do not metastasize to the contralateral tibia during the experimental period and they only cause structural degradation of bones in the ipsilateral limb but not the contralateral limb (Kurth et al., 2001, 2002). They also generally do not metastasize to highly perfused organs such as the lungs (Brigatte et al., 2007), in contrast to other cell lines such as the 13762 rat mammary carcinoma cell line or the c-SST2 rat mammary carcinoma cell line, which spontaneously metastasize (Blouin et al., 2005).
Although, many scientists tend to presume that tumor cell lines behave indefinitely in a uniform manner (Lewis et al., 2013), changes may be induced by factors such as extended in vitro growth time, high passage number and cross contamination with other cell lines (Sacchi et al., 1984; Chang-Liu and Woloschak, 1997; Buehring et al., 2004; Liscovitch and Ravid, 2007). Immortalized cancer cell lines may also evolve in vivo over time in the animal models in which cancer is induced (Poste et al., 1982b). Various heterogeneous subpopulations of tumor cells within a tumor mass possess diverse metastatic potential and different propensities for metastasis to various organs (Fidler, 1978; Poste et al., 1982a). Similarly, immortalized Walker 256 cancer cell lines from different cell banks may possess diverse characteristics and behavior in vivo despite the fact that these cell lines are from rat origin and are without contamination (Lewis et al., 2013). In general, cell lines may be authenticated by short tandem repeat (STR) profiling of the microsatellite regions of DNA (Nims et al., 2010). However, as there is no reference DNA profile of the Walker 256 cell line (Lewis et al., 2013), researchers typically procure cells of a defined passage number from reputable cell banks. To minimize within- and between- laboratory variability in the use of these cells in vivo, it is important that cultured cells are banked and frozen at early passages, and that culture conditions including growth media, temperature, humidity and exposure to drugs are standardized (Marx, 2014).
General methodology
Although there are minor between-laboratory variations, the general method for induction of breast CIBP in rats has several aspects in common. The procedure generally involves making an incision to the skin and muscle around the knee joint of the anesthetized rat and injecting cancer cells into the tibial bone, followed by sealing of the drilled hole with bone wax, suturing of the wound and close monitoring of animals during post-surgical recovery (Mao-Ying et al., 2006). Cells can also be injected in the femur (Gui et al., 2013, 2015). Small differences in the number of injected Walker 256 cancer cells due to experimental errors typically have a minimal effect on the study outcome (Kurth et al., 2001). The physical process for injection of Walker 256 cells into the medullary canal of the bone does not impact the study outcome adversely as emphasized by the normal fibroblastic healing response around the drilled hole of injected bone (Kurth et al., 2002; Mao-Ying et al., 2006). Although outflow of cells during the injection process can be a common occurrence associated with the model, the syringe can be left in place inside the medullary canal of the bone for an additional 1 or 2 min to avoid leakage of cells along the injection track (Mao-Ying et al., 2006; Yu et al., 2009; Miao et al., 2010; Dong et al., 2011; Hu S. et al., 2012).
Time frame for development of pain behaviors and analgesic efficacy testing
One of the most important and critical factors in the study of pain behavior and extent of bone destruction in this model is the timing of observations post-surgery (Qiu et al., 2012). Large tumors can develop in just a few days (Justice, 1985). However, the time period for development of pain behaviors may vary between studies based upon factors such as cell invasiveness and sex of the experimental animals (Wang et al., 2011). Pain behavior due to the surgical process may be evoked in the ipsilateral (injected) hind paws if the animals are tested immediately after the inoculation surgery (Lan et al., 2010; Dong et al., 2011). Hence a recovery period of 2–3 days post-surgery must be provided for the animals (Wang et al., 2011). For the purposes of studying different mechanisms of breast CIBP and for efficacy profiling of molecules with potential to be developed as novel analgesic agents, it is best to avoid extending the model beyond 20–25 days post-surgery (Mao-Ying et al., 2006; Yu et al., 2009; Cao et al., 2010; Tong et al., 2010; Hang et al., 2014) due to overall poor animal health and ethical concerns (Kurth et al., 2001). In particular, prolonged observation times may be associated with more complex pathophysiology arising from systemic metastasis due to severe osteolysis (Qiu et al., 2012). Hence, the period between days 6 and 18 post-ITI is typically chosen for investigation of breast CIBP mechanisms and the efficacy testing of novel compounds with potential as analgesic agents (Wang et al., 2011; Hu et al., 2012a; Wang L. N. et al., 2012b).
Nature of pain manifestation
In Walker 256 cell-CIBP, up-regulated expression and release of pro-inflammatory mediators including prostaglandin E2 (PGE2), nerve growth factor (NGF), and proinflammatory cytokines including interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) in the spinal cord and dorsal root ganglia contributes to the pathogenesis of bone pain in rats (Cao et al., 2010; Lan et al., 2010; Liu et al., 2010; Dong et al., 2011; Mao-Ying et al., 2012; Yao et al., 2016; Zhu et al., 2016). Hence, neuroinflammation is an important pathogenic characteristic of this model (Hu S. et al., 2012; Song et al., 2015).
Similar to the clinical situation, Walker 256 cell-CIBP manifests as spontaneous pain, hyperalgesia, allodynia as well as ambulatory pain, the severity of which largely depends upon the number of inoculated cells, but can also be affected by other experimental factors including cell origin as well as strain or sex of the animals used (Mao-Ying et al., 2006; Liu et al., 2010). Similarly, hind paw hypersensitivity induced by ITI with Walker 256 cells may be either unilateral (Liu et al., 2010; Tong et al., 2010; Dong et al., 2011; Wang J. et al., 2012; Wang L. N. et al., 2012b) or bilateral (Mao-Ying et al., 2006, 2012; Zhao et al., 2013; Li et al., 2014). Peripheral mechanisms including circulating factors and transmedian sprouting, or central mechanisms such as signaling via commissural interneurons in the spinal cord and brain stem may underpin unilateral injury-induced contralateral mirror effects (Koltzenburg et al., 1999). This mirror image effect may also be correlated with spinal glia cell activation, proinflammatory cytokine production, and morphological changes within the local nerve, suggesting the involvement of glia (Chacur et al., 2001). The mirror image pain behavior induced in the contralateral hind paw in this model may be observed when the tumors are in the advanced stage (Miao et al., 2010; Zhao et al., 2013; Li et al., 2014) Typically though, contralateral pain behaviors are of reduced intensity compared with the ipsilateral hind paw (Miao et al., 2010).
Thermal and mechanical pain behaviors are underpinned by different mechanisms (Paqueron et al., 2003; Wang J. et al., 2012). Cutaneous nociceptors are particularly sensitized by thermal stimuli and nociceptors present in deep somatic tissues such as joints and muscle exhibit pronounced sensitization to mechanical stimuli (Schaible, 2007). Although, thermal hyperalgesia has been reported in this model (Liu et al., 2011; Duan et al., 2012; Wang J. et al., 2012), there are several studies in which hindpaw hypersensitivity to an applied noxious heat stimulus is not observed in rats following a unilateral ITI of Walker 256 cells (Mao-Ying et al., 2006, 2012; Yao et al., 2008; Miao et al., 2010; Wang et al., 2011). Again, these differences may be attributed to various factors including between-vendor differences in animals and cancer cell-related factors. For this reason, thermal hyperalgesia is not typically used as a pain behavioral endpoint in this model (Yu et al., 2009; Cao et al., 2010; Tong et al., 2010; Zhao et al., 2010; Dong et al., 2011). A between-study comparison of Walker 256 cell- CIBP rat model is presented in Table 1.
Table 1
| Number of cells injected | Rat Sex, Strain- (Number of studies) | Time frame of hind paw hypersensitivity post- ITI (Days) | Nature of pain behavioral responses in the hind paw | References | |||
|---|---|---|---|---|---|---|---|
| MA | MH | TH | S/MEP | ||||
| 4 × 103 | F, W- (1) | 14–19 | + | NA | NA | + | Cao et al., 2010 |
| 5 × 103 | F, SD- (1) | 6–14 | + | NA | NA | NA | Zhao et al., 2013 |
| 1 × 104 | F, W- (1) | 9–21 | + | NA | NA | + | Ke et al., 2013 |
| 1 × 104 | F, SD- (1) | 7–18 | + | NA | + | + | Yao et al., 2016 |
| 3 × 104 | F, SD- (1) | Tested day 10 | + | NA | NA | NA | Liu et al., 2012 |
| 4 × 104 | F, W- (3) | 3–16 | + | NA | NA | NA | Dong et al., 2011; Bu et al., 2014; Xia et al., 2014; Ye et al., 2014; Guan et al., 2015 |
| F, SD- (2) | |||||||
| 5 × 104 | F, SD- (2) | 7–18 | + | NA | + | NA | Qiu et al., 2014; Wang et al., 2016 |
| 5 × 104 | F, SD- (1) | 5–14 | NA | + | + | NA | Qiu et al., 2012 |
| 1 × 105 | F, W- (2) | 12–24 | + | NA | + | + | Bao et al., 2014b, 2015c |
| 1 × 105 | M&F, SD- (4) | 5–28 | + | NA | + | NA | Liu et al., 2011; Jiang et al., 2014; Bao et al., 2015a; Fan et al., 2015; Jiang et al., 2015; Ren et al., 2015; Jiang et al., 2016 |
| M&F, W- (3) | |||||||
| 1 × 105 | F, SD- (8) | 6–21 | + | NA | NA | + | Lan et al., 2010; Liu et al., 2010; Chen et al., 2012; Hang et al., 2012; Wang L. N. et al., 2012a,b; Jin et al., 2014; Bian et al., 2016 |
| 1 × 105 | F, SD- (8) | 5–21 | + | NA | NA | NA | Wang et al., 2011; Hu et al., 2012a,b; Hang et al., 2013b,c; Hu et al., 2013; Hang et al., 2015, 2016; Zhu et al., 2015 |
| F, W- (1) | |||||||
| 1 × 105 | F, SD- (1) | 6–15 | NA | + | NA | + | Hang et al., 2014 |
| 1 × 105 | F, SD- (1) | 6–15 | NA | + | NA | NA | Hang et al., 2013a |
| 1 × 105 | F, W- (1) | Tested day 14 | NA | NA | NA | + | Bao et al., 2015b |
| 2 × 105 | F, SD- (2) | 3–21 | + | NA | NA | NA | Huang et al., 2014; Jin et al., 2015; Pan R. et al., 2015; Wu J. X. et al., 2016 |
| F, W- (1) | |||||||
| 2 × 105 | F, W- (1) | 7–21 | NA | + | − | + | Miao et al., 2010 |
| 2 × 105 | F, SD- (1) | 7–25 | NA | + | − | NA | Li et al., 2014 |
| 2 × 105 | F, W- (1) | 7–21 | NA | + | + | + | Wu et al., 2012 |
| 3.5 × 105 | F, SD- (2) | 5–21 | + | NA | + | NA | Wang J. et al., 2012; Wang et al., 2015 |
| 4 × 105 | F, SD- (1) | 5–21 | + | NA | − | + | Yin et al., 2010 |
| 4 × 105 | F, SD- (1) | 4–32 | + | NA | − | NA | Huang et al., 2012; Mao-Ying et al., 2012 |
| F, W- (1) | |||||||
| 4 × 105 | F, W- (2) | 7–21 | + | NA | + | + | Duan et al., 2012; Yang et al., 2015; Zhou et al., 2015 |
| F, SD- (1) | |||||||
| 4 × 105 | SD- (1) | 3–21 | + | NA | NA | + | Cheng et al., 2014 |
| 4 × 105 | M&F, W- (10) | 3–21 | + | NA | NA | NA | Yu et al., 2009; Tong et al., 2010; Hu S. et al., 2012; Wang X. W. et al., 2012a,b; Li et al., 2013; Zhang et al., 2013; Gong et al., 2014; Zhu B. et al., 2014; Hu S. et al., 2015; Li et al., 2016; Song et al., 2016 |
| F, SD- (2) | |||||||
| 4 × 105 | F, W- (1) | 6–20 | NA | NA | + | NA | Xu et al., 2013 |
| 5 × 105 | F, SD- (1) | 7–21 | + | NA | + | + | Liu et al., 2013 |
| 5 × 105 | F, SD- (5) | 5–21 | + | NA | + | NA | Bao et al., 2014a; Liu et al., 2014; Shen et al., 2014; Hu X. M. et al., 2015; Zhang et al., 2015; Zhu et al., 2016 |
| F, W- (1) | |||||||
| 5 × 105 | F, SD- (1) | 7–10 | + | NA | NA | + | Lu et al., 2015 |
| 5 × 105 | F, SD- (3) | 9–21 | + | NA | NA | NA | Chen et al., 2013, 2015; Song et al., 2015 |
| 5 × 105 | F, SD- (1) | 7–10 | NA | + | NA | + | Lu et al., 2016 |
| 5 × 105 | M, SD- (1) | 5–14 | NA | + | NA | NA | Xu et al., 2015 |
| 1 × 108 | F, SD- (1) | 7–25 | + | NA | NA | NA | Zhao et al., 2010 |
Comparative summary of previous work by others using the Walker 256 cell-CIBP model in rats.
+, observed; −, not observed; F, female; M, male; MA, mechanical allodynia; MH, mechanical hyperalgesia; NA, not assessed; SD, Sprague Dawley; S/MEP, spontaneous or movement- evoked pain; TH, thermal hyperalgesia; W, Wistar.
Regression of tumor and resolution of pain
Similar to the well-known human scenario of breast cancer regression (Lewison, 1976; Hutter, 1982; Burnside et al., 2006; Barry, 2009; Onuigbo, 2012), Walker 256 breast cancer cells may also potentially transform into a regressive variant in vivo (Guimarães et al., 2010) resulting in complete regression if the study is prolonged (Jensen and Muntzing, 1970; Cavalcanti et al., 2003; Schanoski et al., 2004). The mechanisms underlying spontaneous regression are not entirely clear but may involve development of an adaptive immune response (Pardoll and Topalian, 1998; Rees and Mian, 1999), differential propagation of tumor sub clones in their microenvironment (Khong and Restifo, 2002) and consequent elimination by immune cells, antibodies, cytokines, and chemokines (Dunn et al., 2002, 2006; Bui and Schreiber, 2007; Jaganjac et al., 2008). Physical activity of the animals, exercise (Hoffman et al., 1962; Deminice et al., 2016b), dietary factors (Bekesi and Winzler, 1970; Kwong et al., 1984; Luty et al., 2016), or hormonal levels (Khegai, 2013; Khegay and Ivanova, 2015) may influence the regression of these cells or inhibit the activities driven by these cells (Campos-Ferraz et al., 2016; Cruz et al., 2016; Deminice et al., 2016a; Fracaro et al., 2016; Toneto et al., 2016). In most studies, tumor regression is generally overlooked as the tumor-bearing rats are sacrificed before regression is evident (Guimarães et al., 2010). Thus, the verification of tibial tumor burden post-mortem is very important. However, the beginning of pain behavior resolution at 20–25 days post-surgery is typically not due to tumor regression, but may involve neuro-immune mechanisms (Zhao et al., 2010; Xu et al., 2013; Huang et al., 2014). In previous work by others using different cancer cell lines, up regulation of the endogenous opioid system is implicated in spontaneous pain behavior resolution (Muralidharan et al., 2013). Similarly, endogenous opioid system could also have a role in Walker 256 cell-CIBP model (Li et al., 2016). In addition, lipoxins and endogenous lipoxygenase-derived eicosanoids, which represent a unique class of lipid mediators, have a broad spectrum of anti-inflammatory and antinociceptive activities. These are known to suppress the expression of spinal pro-inflammatory cytokines and might also contribute to spontaneous resolution of Walker 256 cell-CIBP in rats (Hu S. et al., 2012). Inflammation, which is an important component of cancer pain (Falk and Dickenson, 2014) mostly involves active endogenous processes targeted at protecting the host, and is generally self-limiting and self-resolving (Chiang et al., 2005; Serhan and Savill, 2005; Schwab and Serhan, 2006).
Targets for novel analgesic drug discovery
The pathobiology of Walker 256 cell-CIBP in rats is complex involving inflammatory, neuropathic and tumorigenic components (Cao et al., 2010). Following injection, these cells cause osteolysis and bone resorption (Kurth et al., 2000, 2001; Yu et al., 2009) and increase oxidative stress and impair the antioxidant system in the bone microenvironment (Badraoui et al., 2009). They cause enhanced synthesis of IL-1β and TNF-α at the mRNA or protein level along with nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which indicates that increased neuroimmune responses is one of the important factors responsible for pain in this model (Cao et al., 2010; Song et al., 2016). Injection of these cells in the bones sequentially activates the extracellular signal-regulated protein kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway in various cell types in the spinal cord of rats (Wang et al., 2011; Wang X. W. et al., 2012b; Bian et al., 2016). Sodium channels expressed by sensory nerve fibers including voltage gated sodium ion channels (Nav)1.7, Nav1.8, and Nav1.9 (Miao et al., 2010; Qiu et al., 2012; Pan J. et al., 2015) as well as potassium ion channels, high-voltage-activated calcium channels, hyperpolarization-activated cation channels, transient receptor potential cation channel subfamily V member 1 (TRPV1) (Duan et al., 2012; Xu et al., 2013; Xia et al., 2014), and acid-sensing ion channel 3 (Qiu et al., 2014) may also be important determinants of enhanced neuronal excitability in this breast CIBP model in rats.
Pain behavior and its relief in Walker 256 cell-CIBP in rats is mediated by the endogenous effectors of several targets interacting with their cognate receptors as summarized in Table 2. These include important targets like opioid receptors, toll like receptors, chemokine receptors, and purinergic receptors.
Table 2
| Receptor | Ligand | Downstream molecule/effector | In vivo pharmacological modulator used | References |
|---|---|---|---|---|
| Toll like receptor 4 (TLR4) | Lipopolysaccharide (Saitoh et al., 2004) | TNF- α, IL-1β; IL-6; p38MAPK | Inducible Lentivirus-Mediated small interfering RNA (siRNA) against TLR4; p38MAPK inhibitor- SB203580; TLR4 blocker- lipopolysaccharide Rhodobacter sphaeroides (LPSRS) | Lan et al., 2010; Liu et al., 2010; Mao-Ying et al., 2012; Li et al., 2013; Liu et al., 2013; Pan R. et al., 2015 |
| Lysophosphatidic acid 1 (LPA1) receptor | Lysophosphatidic acid | Phospholipase C, MAPK, protein kinase B (Akt) (Yung et al., 2014), Ras homolog gene family (Rho), Rho- associated protein kinase (ROCK) | LPA1 receptor blocker- VPC32183; Rho inhibitor- BoTXC3; ROCK inhibitor- Y27632 | Zhao et al., 2010; Wu J. X. et al., 2016 |
| Erythropoietin-producing human hepatocellular carcinoma receptor B1 (EphB1) | EphrinB1, EphrinB2 | IL-1, IL-6 and TNF- α; Matrix metalloproteinase (MMP)-2/9 | EphB1 receptor blocker- EphB1-Fc; EphB1 receptor blocker- EphB2-Fc | Dong et al., 2011; Liu et al., 2011 |
| Epidermal growth factor-like receptor ErbB2 | Neuregulin 1 (NRG1) | Akt-1, p38MAPK | ErbB2 inhibitor | Jiang et al., 2014 |
| CX3C chemokine receptor 1 (CX3CR1) | Fractalkine | p38MAPK | Anti-CX3CR1 antibody | Yin et al., 2010; Hu et al., 2012a; Cheng et al., 2014 |
| CC chemokine receptor-2 (CCR2) | Chemokine monocyte chemoattractant protein-1 (MCP-1) | phosphatidylinositol 3-kinase (PI3K), Akt | Anti-MCP-1 antibody; PI3K inhibitor LY294002; exogenous recombinant MCP-1; CCR2 antagonist RS102895 | Hu et al., 2012b, 2013; Jin et al., 2015; Ren et al., 2015 |
| Chemokine (C-X-C motif) receptor CXCR3 | CXCL9, CXCL10, CXCL11 | Phosphoinositide -3 kinase (PI3K), MAPK, Akt, ERK 1/2 (Smit et al., 2003) | Recombinant CXCL10 protein, anti-CXCL10 antibody, CXCR3 antagonist | Bu et al., 2014; Guan et al., 2015 |
| CXC motif receptor 4 (CXCR4) | CXCL12 | TNF-α, NF-κB, IL-6 and MAPKs | Anti-CXCL12 neutralizing Antibody, CXCR4 inhibitor-AMD3100, c-Jun N-terminal kinases (JNK) inhibitor SP600125, MAPK inhibitor U0126, p38 inhibitor SB503580 | Shen et al., 2014; Hu X. M. et al., 2015 |
| Purinergic P2Y1 receptor (P2Y1R) | Extracellular Adenosine triphosphate (ATP) (Webb et al., 1994) | ERK1/2 | P2Y1R antagonist MRS2179 | Chen et al., 2012 |
| Purinergic P2X3 receptor (P2X3R) | Extracellular ATP | ERK (Seino et al., 2006) | P2X3 receptor antagonist- A-317491 | Wu et al., 2012; Zhou et al., 2015 |
| Purinergic P2X4 receptor (P2X4R) | Extracellular ATP (North, 2002) | p38MAPK | P2X4R siRNA | Jin et al., 2014 |
| Purinergic P2X7 receptor (P2X7R) | ATP | IL-1β, IL-18, phosphorylated p38 (Arulkumaran et al., 2011) | inhibitor of P2X7R- Brilliant Blue G (BBG); RNA interference targeting the P2X7R | Huang et al., 2014; Yang et al., 2015 |
| a3 glycine receptors | Glycine | Chloride current modulation (Avila et al., 2013) | siRNA targeting a3 GlyR, glycine receptor antagonist- strychnine | Zhang et al., 2013 |
| Adenosine A1 receptor | Adenosine | Protein kinase C (PKC) (Hughes et al., 2015) | Adenosine A1 receptor antagonist- DPCPX | Chen et al., 2013 |
| Protease-activated receptor 2 (PAR2) | Trypsin and trypsin-like proteinases | NF-κB | PAR2 antagonist- FSLLRY-NH2 | Bao et al., 2014a, 2015b |
| Protease-activated receptor 4 (PAR4) | Thrombin | Vascular endothelial growth factor (VEGF), endostatin (Ma et al., 2005) | None | Bao et al., 2015c |
| Glucagon like peptide-1 receptor (GLP-1R) | Glucagon like peptide-1 (GLP-1) | Cyclic adenosine monophosphate (cAMP), protein kinase A (PKA) | GLP-1R agonists GLP-1(7–36) | Gong et al., 2014 |
| Cannabinoid receptor type 2 (CB2) | 2-arachidonoylglycerol (Basu et al., 2011) | IL-1β, IL-6, IL-18, TNF-α | CB2-selective antagonist- AM630; CB2-selective agonist- JWH-015 | Lu et al., 2015, 2016 |
| Prokineticin receptor 2 (PKR2) | Bv8 (prokineticin 2) | TNF- α | Bv8 neutralizing antibody | Hang et al., 2015 |
| Corticotropin-releasing factor (CRF) receptor | Corticotropin-releasing factor (CRF) | PKA, NF-κB, ERK 1/2 (Taché and Million, 2015) | CRF receptor antagonist (α-helical-CRF) | Fan et al., 2015 |
| μ-opioid receptor (MOR) | Endomorphin-2 | Guanosine triphosphate (GTP), adenosine diphosphate (ADP) (Al-Hasani and Bruchas, 2011) | MOR antagonist- β-funaltrexamine (β-FNA) | Chen et al., 2015; Jiang et al., 2016; Yao et al., 2016 |
| Sigma-1 Receptor | Tryptaminergic trace amines, as well as neuroactive steroids such as dehydroepiandrosterone (DHEA) and pregnenolone (Fontanilla et al., 2009) | Inositol trisphosphate (IP3) | Sigma-1 receptor antagonist -BD1047 | Zhu et al., 2015 |
| N-Methyl-D-Aspartate (NMDA) Receptor | Glutamate, glycine or D-serine (Hogan-Cann and Anderson, 2016) | PKA, MAPK (Zhao et al., 2016) | None | Wang L. N. et al., 2012a |
Role of endogenous effectors interacting with their cognate targets that mediate pain and analgesia in the Walker 256 cell- CIBP model in rats.
Limitations and potential improvement of the model
Like many other preclinical models, this model has short-comings which might hinder translation of promising preclinical data into successful clinical outcomes. Mostly, efficacy profiling in preclinical pain models is driven by a desire to reduce the intensity of pain behavioral readouts. However, a reduction in pain intensity is not always a good measure of the success of a pain treatment (Ballantyne and Sullivan, 2015). Pain is a subjective emotional experience and clinically, a powerful analgesic response can be elicited by placebo treatment (Kaptchuk and Miller, 2015; Tuttle et al., 2015). Hence, responses in experimental animals may not necessarily correlate with the responses expected from humans in the clinical setting. It is also necessary to remember that animals at different ages may process nociception differently (McKelvey et al., 2015) and hence, selection of the correct age of animals that suits the experimental goals may be critical.
Important factors that significantly affect pain research outcomes, such as the sex of the researchers interacting with the animals (Sorge et al., 2014) should not be overlooked in preclinical studies. Sex of the experimental animals or human subjects is a key source of variation in pro-nociceptive signaling (Wiesenfeld-Hallin, 2005; Sorge et al., 2015). In a recent large-scale gene regulatory study (Qu et al., 2015), the main findings were that men and women may require different strategies for treatment of pain, and so sex differences in pain research should not be ignored (Murphy et al., 2009; Vacca et al., 2014, 2016; Brings and Zylka, 2015; Cahill and Aswad, 2015; Ferrarelli, 2015).
There are many types of breast cancer in the clinical setting (Sharma et al., 2010) with the potential to cause pain, and the extent to which this model provides insights into these various subtypes is currently unclear. It is also important to have standardized protocols when using such preclinical models in order to minimize between-investigator and between-laboratory differences in implementation (Freedman and Gibson, 2015).
Conclusion
Cancer-associated pain, especially intractable bone pain, is very debilitating (Kane et al., 2015). Although, this model involving ITI of Walker 256 cells in rats might not exactly mimic the metastatic spread of breast cancer to the axial skeleton in humans (Kurth et al., 2001, 2002), it provides great insights into the pathobiology and mechanisms of breast CIBP and is hence used very widely in experimental research (Du et al., 2015; Hang et al., 2015; Hu S. et al., 2015; Liu et al., 2015; Lu et al., 2015). Undoubtedly, it is one of the most suitable preclinical models for efficacy assessment of novel compounds from discovery programs aimed at identifying drugs with potential to alleviate breast CIBP in humans.
Statements
Author contributions
All authors (PS, AK, IV, and MS) meet the essential authorship criteria required by the journal including (a) substantial contributions to the conception and design of this article; the acquisition, analysis, and interpretation of the work, (b) drafting the work and revising it critically for important intellectual content, (c) final approval of the version to be published, and (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Acknowledgments
PS is supported by The University of Queensland's International PhD Scholarship. AK is supported by Post-Doctoral Fellowship funded by an Australian Research Council Large Linkage Grant (LP120200623) in collaboration with industry (Boehringer Ingelheim Pharma Gmbh & Co. KG). IV is supported by an Australian Research Council Future Fellowship.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- CIBP
cancer- induced bone pain
- ITI
intra-tibial injection.
Abbreviations
References
1
Al-HasaniR.BruchasM. R. (2011). Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology115, 1363–1381. 10.1097/aln.0b013e318238bba6
2
ArulkumaranN.UnwinR. J.TamF. W. K. (2011). A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin. Investig. Drugs20, 897–915. 10.1517/13543784.2011.578068
3
AvilaA.NguyenL.RigoJ. M. (2013). Glycine receptors and brain development. Front. Cell. Neurosci7:184. 10.3389/fncel.2013.00184
4
BadraouiR.BlouinS.MoreauM. F.GalloisY.RebaiT.SahnounZ.et al. (2009). Effect of alpha tocopherol acetate in Walker 256/B cells-induced oxidative damage in a rat model of breast cancer skeletal metastases. Chem. Biol. Interact.182, 98–105. 10.1016/j.cbi.2009.09.010
5
BallantyneJ. C.SullivanM. D. (2015). Intensity of chronic pain–the wrong metric?N. Engl. J. Med.373, 2098–2099. 10.1056/NEJMp1507136
6
BaoY.GaoY.HouW.YangL.KongX.ZhengH.et al. (2015a). Engagement of signaling pathways of protease-activated receptor 2 and mu-opioid receptor in bone cancer pain and morphine tolerance. Int. J. Cancer137, 1475–1483. 10.1002/ijc.29497
7
BaoY.HouW.LiuR.GaoY.KongX.YangL.et al. (2014a). PAR2-mediated upregulation of BDNF contributes to central sensitization in bone cancer pain. Mol. Pain10:28. 10.1186/1744-8069-10-28
8
BaoY.HouW.YangL.KongX.DuM.ZhengH.et al. (2015b). Protease-activated receptor 2 antagonist potentiates analgesic effects of systemic morphine in a rat model of bone cancer pain. Reg. Anesth. Pain Med.40, 158–165. 10.1097/aap.0000000000000211
9
BaoY.HouW.YangL.LiuR.GaoY.KongX.et al. (2015c). Increased expression of protease-activated receptor 2 and 4 within dorsal root ganglia in a rat model of bone cancer pain. J. Mol. Neurosci.55, 706–714. 10.1007/s12031-014-0409-1
10
BaoY.HuaB.HouW.ShiZ.LiW.LiC.et al. (2014b). Involvement of protease-activated receptor 2 in nociceptive behavior in a rat model of bone cancer. J. Mol. Neurosci.52, 566–576. 10.1007/s12031-013-0112-7
11
BarryI. (2009). The regression question. Nat. Rev. Cancer9, 8–8. 10.1038/nrc2575
12
BasuS.RayA.DittelB. N. (2011). Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J. Immunol.187, 5720–5732. 10.4049/jimmunol.1102195
13
BekesiJ. G.WinzlerR. J. (1970). Inhibitory effects of d-glucosamine on the growth of walker 256 Carcinosarcoma and on protein, RNA, and DNA synthesis. Cancer Res.30, 2905–2912.
14
BianJ.ZhuS.MaW.LiC.AshrafM. A. (2016). Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain. Saudi Pharm. J.24, 354–362. 10.1016/j.jsps.2016.04.017
15
BlouinS.BasléM. F.ChappardD. (2005). Rat models of bone metastases. Clin. Exp. Metastasis22, 605–614. 10.1007/s10585-006-9002-5
16
BrigatteP.FaiadO. J.Ferreira NocelliR. C.LandgrafR. G.PalmaM. S.CuryY.et al. (2016). Walker 256 tumor growth suppression by crotoxin involves formyl peptide receptors and lipoxin A4. Mediators Inflamm.2016:2457532. 10.1155/2016/2457532
17
BrigatteP.SampaioS. C.GutierrezV. P.GuerraJ. L.SinhoriniI. L.CuriR.et al. (2007). Walker 256 tumor-bearing rats as a model to study cancer pain. J. Pain8, 412–421. 10.1016/j.jpain.2006.11.006
18
BringsV. E.ZylkaM. J. (2015). Sex, drugs and pain control. Nat. Neurosci.18, 1059–1060. 10.1038/nn.4057
19
BuH.ShuB.GaoF.LiuC.GuanX.KeC.et al. (2014). Spinal IFN-gamma-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models. Breast Cancer Res. Treat.143, 255–263. 10.1007/s10549-013-2807-4
20
BuehringG. C.EbyE. A.EbyM. J. (2004). Cell line cross-contamination: how aware are Mammalian cell culturists of the problem and how to monitor it?In Vitro Cell. Dev. Biol. Anim.40, 211–215. 10.1290/1543-706x(2004)40<211:clchaa>2.0.co;2
21
BuiJ. D.SchreiberR. D. (2007). Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?Curr. Opin. Immunol.19, 203–208. 10.1016/j.coi.2007.02.001
22
BurnsideE. S.Trentham-DietzA.KelczF.CollinsJ. (2006). An example of breast cancer regression on imaging. Radiol. Case Rep.1, 27–37. 10.2484/rcr.v1i2.4
23
CahillL.AswadD. (2015). Sex influences on the brain: an issue whose time has come. Neuron88, 1084–1085. 10.1016/j.neuron.2015.11.021
24
Campos-FerrazP. L.GualanoB.das NevesW.AndradeI. T.HangaiI.PereiraR. T.et al. (2016). Exploratory studies of the potential anti-cancer effects of creatine. Amino Acids48, 1993–2001. 10.1007/s00726-016-2180-9
25
CaoF.GaoF.XuA. J.ChenZ. J.ChenS. S.YangH.et al. (2010). Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain. Brain Res.1326, 162–173. 10.1016/j.brainres.2010.02.039
26
CavalcantiT. C.GregoriniC. C.GuimarãesF.RettoriO.Vieira-MatosA. N. (2003). Changes in red blood cell osmotic fragility induced by total plasma and plasma fractions obtained from rats bearing progressive and regressive variants of the Walker 256 tumor. Braz. J. Med. Biol. Res.36, 887–895. 10.1590/S0100-879X2003000700009
27
ChacurM.MilliganE. D.GazdaL. S.ArmstrongC.WangH.TraceyK. J.et al. (2001). A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain94, 231–244. 10.1016/S0304-3959(01)00354-2
28
Chang-LiuC. M.WoloschakG. E. (1997). Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression. Cancer Lett.113, 77–86. 10.1016/S0304-3835(97)04599-0
29
ChenJ.WangL.ZhangY.YangJ. (2012). P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain. Acta Biochim. Biophys. Sin. (Shanghai).44, 367–372. 10.1093/abbs/gms007
30
ChenL.WangK.YangT.WangW.MeiX. P.ZhuC.et al. (2015). Downregulation of spinal endomorphin-2 correlates with mechanical allodynia in a rat model of tibia cancer. Neuroscience286, 151–161. 10.1016/j.neuroscience.2014.11.049
31
ChenL.ZhuL.WangK.WangW.MeiX. P.LiuT.et al. (2013). Antinociceptive effect of prostatic acid phosphatase in a rat model of cancer-induced bone pain. Pain Physician16, 533–546.
32
ChengW.ZhaoY.LiuH.FanQ.LuF. F.LiJ.et al. (2014). Resveratrol attenuates bone cancer pain through the inhibition of spinal glial activation and CX3CR1 upregulation. Fundam. Clin. Pharmacol.28, 661–670. 10.1111/fcp.12084
33
ChiangN.AritaM.SerhanC. N. (2005). Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids73, 163–177. 10.1016/j.plefa.2005.05.003
34
ColemanR. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res.12(20 Pt 2), 6243s–6249s. 10.1158/1078-0432.CCR-06-0931
35
ColvinL.FallonM. (2008). Challenges in cancer pain management–bone pain. Eur. J. Cancer44, 1083–1090. 10.1016/j.ejca.2008.03.001
36
CruzB. L.da SilvaP. C.TomasinR.OliveiraA. G.VianaL. R.SalomaoE. M.et al. (2016). Dietary leucine supplementation minimises tumour-induced damage in placental tissues of pregnant, tumour-bearing rats. BMC Cancer16:58. 10.1186/s12885-016-2103-x
37
CurrieG. L.DelaneyA.BennettM. I.DickensonA. H.EganK. J.VesterinenH. M.et al. (2013). Animal models of bone cancer pain: systematic review and meta-analyses. Pain154, 917–926. 10.1016/j.pain.2013.02.033
38
DeminiceR.CellaP. S.PadilhaC. S.BorgesF. H.da SilvaL. E.Campos-FerrazP. L.et al. (2016a). Creatine supplementation prevents hyperhomocysteinemia, oxidative stress and cancer-induced cachexia progression in Walker-256 tumor-bearing rats. Amino Acids48, 2015–2024. 10.1007/s00726-016-2172-9
39
DeminiceR.PadilhaC. S.BorgesF.da SilvaL. E.RosaF. T.RobinsonJ. L.et al. (2016b). Resistance exercise prevents impaired homocysteine metabolism and hepatic redox capacity in Walker-256 tumor-bearing male Wistar rats. Nutrition32, 1153–1158. 10.1016/j.nut.2016.03.008
40
DongY.Mao-YingQ. L.ChenJ. W.YangC. J.WangY. Q.TanZ. M. (2011). Involvement of EphB1 receptor/ephrinB1 ligand in bone cancer pain. Neurosci. Lett.496, 163–167. 10.1016/j.neulet.2011.04.008
41
DuJ.FangJ.ChenY.WuS.LiangY.FangJ. (2015). [Parametric optimization of electroacupuncture against bone-cancer pain in rats and its intervention on mRNA expression of opioid receptor and precursor]. Zhongguo Zhen Jiu35, 161–168.
42
DuanK. Z.XuQ.ZhangX. M.ZhaoZ. Q.MeiY. A.ZhangY. Q. (2012). Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model. Pain153, 562–574. 10.1016/j.pain.2011.11.020
43
DunnG. P.BruceA. T.IkedaH.OldL. J.SchreiberR. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol.3, 991–998. 10.1038/ni1102-991
44
DunnG. P.KoebelC. M.SchreiberR. D. (2006). Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol.6, 836–848. 10.1038/nri1961
45
EarleW. R. (1935). A study of the walker rat mammary carcinoma 256, in vivo and in vitro. Am. J. Cancer24, 566–612.
46
FalkS.DickensonA. H. (2014). Pain and nociception: mechanisms of cancer-induced bone pain. J. Clin. Oncol.32, 1647–1654. 10.1200/JCO.2013.51.7219
47
FallonM.HoskinP. J.ColvinL. A.Fleetwood-WalkerS. M.AdamsonD.ByrneA.et al. (2016). Randomized double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain. J. Clin. Oncol.34, 550–556. 10.1200/JCO.2015.63.8221
48
FanH.Xiao-LingS.YaliuS.Ming-MingL.XueF.Xian-ShengM.et al. (2016). Comparative pharmacokinetics of ginsenoside Rg3 and ginsenoside Rh2 after oral administration of ginsenoside Rg3 in normal and walker 256 tumor-bearing rats. Pharmacogn. Mag.12, 21–24. 10.4103/0973-1296.176014
49
FanH. B.ZhangT.SunK.SongS.-P.CaoS.-B.ZhangH.-L.et al. (2015). Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord. Tumor Biol.36, 9559–9565. 10.1007/s13277-015-3670-1
50
FernandesC.MonteiroS.BelchiorA.MarquesF.GanoL.CorreiaJ. D.et al. (2016). Novel (188)Re multi-functional bone-seeking compounds: synthesis, biological and radiotoxic effects in metastatic breast cancer cells. Nucl. Med. Biol.43, 150–157. 10.1016/j.nucmedbio.2015.11.004
51
FerrarelliL. (2015). Why women feel more pain. Sci. Signal.8, ec212. 10.1126/scisignal.aad1342
52
FidlerI. J. (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res.38, 2651–2660.
53
FontanillaD.JohannessenM.HajipourA. R.CozziN. V.JacksonM. B.RuohoA. E. (2009). The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science323, 934–937. 10.1126/science.1166127
54
FracaroL.FrezF. C.SilvaB. C.VicentiniG. E.de SouzaS. R.MartinsH. A.et al. (2016). Walker 256 tumor-bearing rats demonstrate altered interstitial cells of Cajal. Effects on ICC in the Walker 256 tumor model. Neurogastroenterol. Motil.28, 101–115. 10.1111/nmo.12702
55
FreedmanL. P.GibsonM. C. (2015). The impact of preclinical irreproducibility on drug development. Clin. Pharmacol. Ther.97, 16–18. 10.1002/cpt.9
56
GaluppoL. F.Dos Reis LíveroF. A.MartinsG. G.CardosoC. C.BeltrameO. C.KlassenL. M.et al. (2016). Sydnone 1: a mesoionic compound with antitumoral and haematological effects in vivo. Basic Clin. Pharmacol. Toxicol.119, 41–50. 10.1111/bcpt.12545
57
GambetaE.KopruszinskiC. M.Dos ReisR. C.ZanoveliJ. M.ChichorroJ. G. (2016). Evaluation of heat hyperalgesia and anxiety like-behaviors in a rat model of orofacial cancer. Neurosci. Lett.619, 100–105. 10.1016/j.neulet.2016.03.001
58
GaoH.ZhuJ.LiY.FuP.ShenB. (2016). Inhibitory effect of endostatin gene therapy combined with phosphorus-32 colloid on tumor growth in Wistar rats. Biosci. Rep.36:e00353. 10.1042/BSR20160117
59
GongN.XiaoQ.ZhuB.ZhangC. Y.WangY. C.FanH.et al. (2014). Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J. Neurosci.34, 5322–5334. 10.1523/JNEUROSCI.4703-13.2014
60
GuanX. H.FuQ. C.ShiD.BuH. L.SongZ. P.XiongB. R.et al. (2015). Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats. Exp. Neurol.263, 39–49. 10.1016/j.expneurol.2014.09.019
61
GuiQ.XuC.LiD.ZhuangL.XiaS.YuS. (2015). Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases. Mol. Med. Rep.12, 4243–4249. 10.3892/mmr.2015.3948
62
GuiQ.XuC.ZhuangL.XiaS.ChenY.PengP.et al. (2013). A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level. Cancer Biol. Ther.14, 193–199. 10.4161/cbt.23291
63
GuimarãesF.SchanoskiA. S.CavalcantiT. C. S.JulianoP. B.Viera-MatosA. N.RettoriO. (2010). Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor. Braz. Arch. Biol. Technol.53, 1101–1108. 10.1590/S1516-89132010000500014
64
HahnT.SzaboL.GoldM.RamanathapuramL.HurleyL. H.AkporiayeE. T. (2006). Dietary administration of the proapoptotic vitamin E analogue alpha-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res.66, 9374–9378. 10.1158/0008-5472.CAN-06-2403
65
HangL.-H.LiS.-N.LuoH.ShuW.-W.MaoZ.-M.ChenY.-F.et al. (2016). Connexin 43 mediates CXCL12 production from spinal dorsal horn to maintain bone cancer pain in rats. Neurochem. Res.41, 1200–1208. 10.1007/s11064-015-1815-7
66
HangL. H.LiS. N.ShaoD. H.ChenZ.ChenY. F.ShuW. W. (2014). Evidence for involvement of spinal RANTES in the antinociceptive effects of triptolide, a diterpene triepoxide, in a rat model of bone cancer pain. Basic Clin. Pharmacol. Toxicol.115, 477–480. 10.1111/bcpt.12265
67
HangL. H.LuoH.LiS. N.ShuW. W.ChenZ.ChenY. F.et al. (2015). Involvement of spinal bv8/prokineticin 2 in a rat model of cancer-induced bone pain. Basic Clin. Pharmacol. Toxicol. 117, 180–185. 10.1111/bcpt.12386
68
HangL.-H.ShaoD.-H.ChenZ.ChenY.-F.ShuW.-W.ZhaoZ.-G. (2013a). Involvement of spinal CC chemokine ligand 5 in the development of bone cancer pain in rats. Basic Clin. Pharmacol. Toxicol.113, 325–328. 10.1111/bcpt.12099
69
HangL.-H.ShaoD. H.ChenZ.SunW. J. (2013b). Spinal RhoA/Rho kinase signalling pathway may participate in the development of bone cancer pain. Basic Clin. Pharmacol. Toxicol.113, 87–91. 10.1111/bcpt.12069
70
HangL. H.YangJ. P.ShaoD. H.ChenZ.WangH. (2013c). Involvement of spinal PKA/CREB signaling pathway in the development of bone cancer pain. Pharmacol. Rep.65, 710–716. 10.1016/S1734-1140(13)71049-1
71
HangL. H.YangJ. P.YinW.WangL. N.GuoF.JiF. H.et al. (2012). Activation of spinal TDAG8 and its downstream PKA signaling pathway contribute to bone cancer pain in rats. Eur. J. Neurosci.36, 2107–2117. 10.1111/j.1460-9568.2012.08087.x
72
HoffmanS. A.PaschkisK. E.DebiasD. A.CantarowA.WilliamsT. L. (1962). The influence of exercise on the growth of transplanted rat tumors. Cancer Res.22, 597–599.
73
Hogan-CannA. D.AndersonC. M. (2016). Physiological roles of non-neuronal NMDA receptors. Trends Pharmacol. Sci.37, 750–767. 10.1016/j.tips.2016.05.012
74
HuJ. H.WuM. Y.TaoM.YangJ. P. (2013). Changes in protein expression and distribution of spinal CCR2 in a rat model of bone cancer pain. Brain Res.1509, 1–7. 10.1016/j.brainres.2013.03.002
75
HuJ. H.YangJ. P.LiuL.LiC. F.WangL. N.JiF. H.et al. (2012a). Involvement of CX3CR1 in bone cancer pain through the activation of microglia p38 MAPK pathway in the spinal cord. Brain Res.1465, 1–9. 10.1016/j.brainres.2012.05.020
76
HuJ. H.ZhengX. Y.YangJ. P.WangL. N.JiF. H. (2012b). Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancer-induced bone pain in rats. Neurosci. Lett.517, 60–63. 10.1016/j.neulet.2012.04.026
77
HuS.ChenY.WangZ. F.Mao-YingQ. L.MiW. L.JiangJ. W.et al. (2015). The analgesic and antineuroinflammatory effect of baicalein in cancer-induced bone pain. Evid. Based Complement. Alternat. Med.2015:973524. 10.1155/2015/973524
78
HuS.Mao-YingQ. L.WangJ.WangZ. F.MiW. L.WangX. W.et al. (2012). Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines. J. Neuroinflamm.9:278. 10.1186/1742-2094-9-278
79
HuX. M.LiuY. N.ZhangH. L.CaoS. B.ZhangT.ChenL. P.et al. (2015). CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. J. Neurochem.132, 452–463. 10.1111/jnc.12985
80
HuangJ. L.ChenX. L.GuoC.WangY. X. (2012). Contributions of spinal D-amino acid oxidase to bone cancer pain. Amino Acids43, 1905–1918. 10.1007/s00726-012-1390-z
81
HuangZ. X.LuZ. J.MaW. Q.WuF. X.ZhangY. Q.YuW. F.et al. (2014). Involvement of RVM-expressed P2X7 receptor in bone cancer pain: mechanism of descending facilitation. Pain155, 783–791. 10.1016/j.pain.2014.01.011
82
HughesS. J.CravetchiX.VilasG.HammondJ. R. (2015). Adenosine A1 receptor activation modulates human equilibrative nucleoside transporter 1 (hENT1) activity via PKC-mediated phosphorylation of serine-281. Cell. Signal.27, 1008–1018. 10.1016/j.cellsig.2015.02.023
83
HutterR. V. P. (1982). Assessment: is cured early cancer truly cancer?CA Cancer J. Clin.32, 2–9.
84
IbrahimT.MercataliL.AmadoriD. (2013). A new emergency in oncology: bone metastases in breast cancer patients (Review). Oncol. Lett.6, 306–310. 10.3892/ol.2013.1372
85
JaganjacM.Poljak-BlaziM.ZarkovicK.SchaurR. J.ZarkovicN. (2008). The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma. Cancer Lett.260, 180–186. 10.1016/j.canlet.2007.10.039
86
JensenG.MüntzingJ. (1970). Differences in the growth of the Walker carcinoma in Sprague-Dawley and Wistar rats. Z. Krebsforsch.74, 55–58. 10.1007/BF00524680
87
JiangJ.ZhangJ.YaoP.WuX.LiK. (2014). Activation of spinal neuregulin 1-ErbB2 signaling pathway in a rat model of cancer-induced bone pain. Int. J. Oncol.45, 235–244. 10.3892/ijo.2014.2429
88
JiangZ.WuS.WuX.ZhongJ.LvA.JiaoJ.et al. (2015). Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via μ-opioid receptor. Int. J. Cancer.138, 2013–2020. 10.1002/ijc.29927
89
JiangZ.WuS.WuX.ZhongJ.LvA.JiaoJ.et al. (2016). Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via micro-opioid receptor. Int. J. Cancer138, 2013–2020. 10.1002/ijc.29927
90
JinD.YangJ. P.HuJ. H.WangL. N.ZuoJ. L. (2015). MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain. Brain Res.1599, 158–167. 10.1016/j.brainres.2014.12.043
91
JinX. H.WangL. N.ZuoJ. L.YangJ. P.LiuS. L. (2014). P2X4 receptor in the dorsal horn partially contributes to brain-derived neurotrophic factor oversecretion and toll-like receptor-4 receptor activation associated with bone cancer pain. J. Neurosci. Res.92, 1690–1702. 10.1002/jnr.23443
92
JusticeA. (1985). Review of the effects of stress on cancer in laboratory animals: importance of time of stress application and type of tumor. Psychol. Bull.98, 108–138. 10.1037/0033-2909.98.1.108
93
KaneC. M.HoskinP.BennettM. I. (2015). Cancer induced bone pain. BMJ350:h315. 10.1136/bmj.h315
94
KaptchukT. J.MillerF. G. (2015). Placebo effects in medicine. N. Eng. J. Med.373, 8–9. 10.1056/NEJMp1504023
95
KeC.LiC.HuangX.CaoF.ShiD.HeW.et al. (2013). Protocadherin20 promotes excitatory synaptogenesis in dorsal horn and contributes to bone cancer pain. Neuropharmacology75, 181–190. 10.1016/j.neuropharm.2013.07.010
96
KhegaiI. I. (2013). [Concordance between vasopressin gene expression and growth of Walker 256 carcinosarcoma in rats]. Genetika49, 538–540. 10.1134/s1022795413030101
97
KhegayI. I.IvanovaL. N. (2015). Regression of Walker 256 carcinosarcoma in vasopressin-deficient Brattleboro rats is accompanied by a changed laminin pattern. Biochem. Genet.53, 1–7. 10.1007/s10528-015-9665-1
98
KhongH. T.RestifoN. P. (2002). Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol.3, 999–1005. 10.1038/ni1102-999
99
KoltzenburgM.WallP. D.McMahonS. B. (1999). Does the right side know what the left is doing?Trends Neurosci.22, 122–127.
100
KurthA. A.KimS. Z.SedlmeyerI.BaussF.SheaM. (2002). Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone30, 300–306. 10.1016/S8756-3282(01)00644-5
101
KurthA. H.KimS. Z.SedlmeyerI.HovyL.BaussF. (2000). Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J. Bone Joint Surg. Br.82, 126–130. 10.1302/0301-620X.82B1.9483
102
KurthA. H.WangC.HayesW. C.SheaM. (2001). The evaluation of a rat model for the analysis of densitometric and biomechanical properties of tumor-induced osteolysis. J. Orthop. Res.19, 200–205. 10.1016/S0736-0266(00)90014-7
103
KwongE.NesheimM. C.DillsW. L.Jr. (1984). The influence of diet on the regression of the Walker carcinosarcoma 256 in rats. J. Nutr.114, 2324–2330.
104
LanL. S.PingY. J.NaW. L.MiaoJ.ChengQ. Q.NiM. Z.et al. (2010). Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. Mol. Pain6:2. 10.1186/1744-8069-6-2
105
LewisK. M.Harford-WrightE.VinkR.GhabrielM. N. (2013). Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours. Cancer Cell Int.13:5. 10.1186/1475-2867-13-5
106
LewisonE. F. (1976). Spontaneous regression of breast cancer. Natl. Cancer Inst. Monogr.44, 23–26.
107
LiT. F.FanH.WangY. X. (2016). Aconitum-derived bulleyaconitine A exhibits antihypersensitivity through direct stimulating dynorphin A expression in spinal microglia. J. Pain17, 530–548. 10.1016/j.jpain.2015.12.015
108
LiX.LiG.WuS.ZhangB.WanQ.YuD.et al. (2014). Antinociceptive effect of intrathecal microencapsulated human pheochromocytoma cell in a rat model of bone cancer pain. Int. J. Mol. Sci.15, 12135–12148. 10.3390/ijms150712135
109
LiX.WangX. W.FengX. M.ZhouW. J.WangY. Q.Mao-YingQ. L. (2013). Stage-dependent anti-allodynic effects of intrathecal Toll-like receptor 4 antagonists in a rat model of cancer induced bone pain. J. Physiol. Sci.63, 203–209. 10.1007/s12576-012-0244-5
110
LiscovitchM.RavidD. (2007). A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett.245, 350–352. 10.1016/j.canlet.2006.01.013
111
LiuC.SongJ.MaoY.LiuX. (2015). Bone metastatic pain palliation in a modified rat bone cancer pain model using 188Re-HEDP therapy. J.Nucl. Med.56(Suppl. 3), 1199.
112
LiuS.LiuW. T.LiuY. P.DongH. L.HenkemeyerM.XiongL. Z.et al. (2011). Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents. Cancer Res.71, 4392–4402. 10.1158/0008-5472.CAN-10-3870
113
LiuS.LiuY. P.SongW. B.SongX. J. (2013). EphrinB-EphB receptor signaling contributes to bone cancer pain via Toll-like receptor and proinflammatory cytokines in rat spinal cord. Pain154, 2823–2835. 10.1016/j.pain.2013.08.017
114
LiuS.YangJ.WangL.JiangM.QiuQ.MaZ.et al. (2010). Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res.1346, 213–223. 10.1016/j.brainres.2010.05.014
115
LiuS.ZhangM. Y.ChenL. P.LiuY. P.LiuG. J. (2014). cGMP and cGMP-dependent protein kinase I pathway in dorsal root ganglia contributes to bone cancer pain in rats. Spine (Phila Pa 1976)39, 1533–1541. 10.1097/BRS.0000000000000456
116
LiuX.BuH.LiuC.GaoF.YangH.TianX.et al. (2012). Inhibition of glial activation in rostral ventromedial medulla attenuates mechanical allodynia in a rat model of cancer-induced bone pain. J. Huazhong Univ. Sci. Technol. Med. Sci.32, 291–298. 10.1007/s11596-012-0051-5
117
Lozano-OndouaA. N.Symons-LiguoriA. M.VanderahT. W. (2013). Cancer-induced bone pain: mechanisms and models. Neurosci. Lett.557(Pt A), 52–59. 10.1016/j.neulet.2013.08.003
118
LuC.LiuY.SunB.SunY.HouB.ZhangY.et al. (2015). Intrathecal injection of JWH-015 attenuates bone cancer pain via time-dependent modification of pro-inflammatory cytokines expression and astrocytes activity in spinal cord. Inflammation38, 1880–1890. 10.1007/s10753-015-0168-3
119
LuC.ShiL.SunB.ZhangY.HouB.SunY.et al. (2016). A single intrathecal or intraperitoneal injection of CB2 receptor agonist attenuates bone cancer pain and induces a time-dependent modification of GRK2. Cell. Mol. Neurobiol. [Epub ahead of print]. 10.1007/s10571-016-0349-0
120
LutyM.KwiecienE.FirlejM.Labedz-MaslowskaA.PawM.MadejaZ.et al. (2016). Curcumin augments the cytostatic and anti-invasive effects of mitoxantrone on carcinosarcoma cells in vitro. Acta Biochim. Pol.. [Epub ahead of print]. 10.18388/abp.2016_1314
121
MaL.PeriniR.McKnightW.DicayM.KleinA.HollenbergM. D.et al. (2005). Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl. Acad. Sci. U.S.A.102, 216–220. 10.1073/pnas.0406682102
122
MantyhP. W.ClohisyD. R.KoltzenburgM.HuntS. P. (2002). Molecular mechanisms of cancer pain. Nat. Rev. Cancer2, 201–209. 10.1038/nrc747
123
Mao-YingQ. L.WangX. W.YangC. J.LiX.MiW. L.WuG. C.et al. (2012). Robust spinal neuroinflammation mediates mechanical allodynia in Walker 256 induced bone cancer rats. Mol. Brain5:16. 10.1186/1756-6606-5-16
124
Mao-YingQ. L.ZhaoJ.DongZ. Q.WangJ.YuJ.YanM. F.et al. (2006). A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem. Biophys. Res. Commun.345, 1292–1298. 10.1016/j.bbrc.2006.04.186
125
MarxV. (2014). Cell-line authentication demystified. Nat. Methods11, 483–488. 10.1038/nmeth.2932
126
McEuenC. S.ThomsonD. L. (1933). The effect of hypophysectomy on the growth of the Walker rat tumour. Br. J. Exp. Pathol. 14, 384–391.
127
McKelveyR.BertaT.OldE.JiR. R.FitzgeraldM. (2015). Neuropathic pain is constitutively suppressed in early life by anti-inflammatory neuroimmune regulation. J. Neurosci.35, 457–466. 10.1523/JNEUROSCI.2315-14.2015
128
MedhurstS. J.WalkerK.BowesM.KiddB. L.GlattM.MullerM.et al. (2002). A rat model of bone cancer pain. Pain96, 129–140. 10.1016/S0304-3959(01)00437-7
129
MiaoX. R.GaoX. F.WuJ. X.LuZ. J.HuangZ. X.LiX. Q.et al. (2010). Bilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cells. BMC Cancer10:216. 10.1186/1471-2407-10-216
130
MichaelsonS.OrcuttJ. A. (1957). Observations on some growth characteristics of the Walker carcinoma 256. Cancer10, 416–418.
131
MogilJ. S. (2009). Animal models of pain: progress and challenges. Nat. Rev. Neurosci.10, 283–294. 10.1038/nrn2606
132
MogilJ. S.GriselJ. E. (1998). Transgenic studies of pain. Pain77, 107–128. 10.1016/S0304-3959(98)00093-1
133
MuralidharanA.WyseB. D.SmithM. T. (2013). Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacol. Biochem. Behav.106, 33–46. 10.1016/j.pbb.2013.02.020
134
MurphyA. Z.SuckowS. K.JohnsM.TraubR. J. (2009). Sex differences in the activation of the spinoparabrachial circuit by visceral pain. Physiol. Behav.97, 205–212. 10.1016/j.physbeh.2009.02.037
135
NimsR. W.SykesG.CottrillK.IkonomiP.ElmoreE. (2010). Short tandem repeat profiling: part of an overall strategy for reducing the frequency of cell misidentification. In Vitro Cell. Dev. Biol. Anim.46, 811–819. 10.1007/s11626-010-9352-9
136
NorthR. A. (2002). Molecular physiology of P2X receptors. Physiol. Rev.82, 1013–1067. 10.1152/physrev.00015.2002
137
OliveiraA. G.Gomes-MarcondesM. C. (2016). Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats. BMC Cancer16:418. 10.1186/s12885-016-2424-9
138
OnuigboW. I. (2012). Spontaneous regression of breast carcinoma: review of English publications from 1753 to 1897. Oncol. Rev.6:e22. 10.4081/oncol.2012.e22
139
PacharinsakC.BeitzA. (2008). Animal models of cancer pain. Comp. Med.58, 220–233.
140
PanJ.LinX.-J.LingZ.-H.CaiY.-Z. (2015). Effect of down—regulation of voltage—gated sodium channel Nav1.7 on activation of astrocytes and microglia in DRG in rats with cancer pain. Asian Pac. J. Trop. Med.8, 405–411. 10.1016/S1995-7645(14)60352-7
141
PanR.DiH.ZhangJ.HuangZ.SunY.YuW.et al. (2015). Inducible Lentivirus-Mediated siRNA against TLR4 Reduces Nociception in a Rat Model of Bone Cancer Pain. Mediators Inflamm.2015:523896. 10.1155/2015/523896
142
PaqueronX.ConklinD.EisenachJ. C. (2003). Plasticity in action of intrathecal clonidine to mechanical but not thermal nociception after peripheral nerve injury. Anesthesiology99, 199–204. 10.1097/00000542-200307000-00030
143
PardollD. M.TopalianS. L. (1998). The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol.10, 588–594. 10.1016/S0952-7915(98)80228-8
144
PigattoM. C.de AraujoB. V.TorresB. G.SchmidtS.MagniP.Dalla CostaT. (2016). Population pharmacokinetic modeling of etoposide free concentrations in solid tumor. Pharm. Res.33, 1657–1670. 10.1007/s11095-016-1906-4
145
PosteG.DollJ.BrownA. E.TzengJ.ZeidmanI. (1982a). Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases. Cancer Res.42, 2770–2778.
146
PosteG.TzengJ.DollJ.GreigR.RiemanD.ZeidmanI. (1982b). Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc. Natl. Acad. Sci. U.S.A.79, 6574–6578.
147
QiuF.JiangY.ZhangH.LiuY.MiW. (2012). Increased expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 within dorsal root ganglia in a rat model of bone cancer pain. Neurosci. Lett.512, 61–66. 10.1016/j.neulet.2012.01.069
148
QiuF.WeiX.ZhangS.YuanW.MiW. (2014). Increased expression of acid-sensing ion channel 3 within dorsal root ganglia in a rat model of bone cancer pain. Neuroreport25, 887–893. 10.1097/WNR.0000000000000182
149
QuK.ZabaL. C.GiresiP. G.LiR.LongmireM.KimY. H.et al. (2015). Individuality and variation of personal regulomes in primary human T cells. Cell Syst.1, 51–61. 10.1016/j.cels.2015.06.003
150
ReesR. C.MianS. (1999). Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol. Immunother.48, 374–381. 10.1007/s002620050589
151
RenF.JiaoH.CaiH. (2015). Analgesic effect of intrathecal administration of chemokine receptor CCR2 antagonist is related to change in spinal NR2B, nNOS, and SIGIRR expression in rat with bone cancer pain. Cell Biochem. Biophys.72, 611–616. 10.1007/s12013-014-0510-7
152
SacchiA.MauroF.ZupiG. (1984). Changes of phenotypic characteristics of variants derived from Lewis lung carcinoma during long-term in vitro growth. Clin. Exp. Metastasis2, 171–178. 10.1007/BF00052417
153
SaitohS.AkashiS.YamadaT.TanimuraN.MatsumotoF.FukaseK.et al. (2004). Ligand-dependent Toll-like receptor 4 (TLR4)-oligomerization is directly linked with TLR4-signaling. J. Endotoxin Res.10, 257–260. 10.1177/09680519040100041001
154
SchaibleH. G. (2007). Peripheral and central mechanisms of pain generation. Handb. Exp. Pharmacol.177, 3–28.
155
SchanoskiA. S.CavalcantiT. C.CamposC. B.Viera-MatosA. N.RettoriO.GuimarãesF. (2004). Walker 256 tumor MHC class I expression during the shift from A variant to the immunogenic AR variant. Cancer Lett.211, 119–127. 10.1016/j.canlet.2004.01.023
156
SchwabJ. M.SerhanC. N. (2006). Lipoxins and new lipid mediators in the resolution of inflammation. Curr. Opin. Pharmacol.6, 414–420. 10.1016/j.coph.2006.02.006
157
SchweiM. J.HonoreP.RogersS. D.Salak-JohnsonJ. L.FinkeM. P.RamnaraineM. L.et al. (1999). Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci.19, 10886–10897.
158
SeinoD.TokunagaA.TachibanaT.YoshiyaS.DaiY.ObataK.et al. (2006). The role of ERK signaling and the P2X receptor on mechanical pain evoked by movement of inflamed knee joint. Pain123, 193–203. 10.1016/j.pain.2006.02.032
159
SerhanC. N.SavillJ. (2005). Resolution of inflammation: the beginning programs the end. Nat. Immunol.6, 1191–1197. 10.1038/ni1276
160
SharmaG. N.DaveR.SanadyaJ.SharmaP.SharmaK. K. (2010). Various types and management of breast cancer: an overview. J. Adv. Pharm. Technol. Res.1, 109–126.
161
ShenW.HuX. M.LiuY. N.HanY.ChenL. P.WangC. C.et al. (2014). CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J. Neuroinflammation11:75. 10.1186/1742-2094-11-75
162
ShihL. Y.ShihH. N.ChenT. H. (2004). Bone resorption activity of osteolytic metastatic lung and breast cancers. J. Orthop. Res.22, 1161–1167. 10.1016/j.orthres.2003.03.004
163
SimmonsJ. K.HildrethB. E.SupsavhadW.ElshafaeS. M.HassanB. B.DirksenW. P.et al. (2015). Animal models of bone metastasis. Vet. Pathol.52, 827–841. 10.1177/0300985815586223
164
SimpkinsH.LehmanJ. M.MazurkiewiczJ. E.DavisB. H. (1991). A morphological and phenotypic analysis of Walker 256 cells. Cancer Res.51, 1334–1338.
165
SloskyL. M.Largent-MilnesT. M.VanderahT. W. (2015). Use of animal models in understanding cancer-induced bone pain. Cancer Growth Metastasis8(Suppl. 1), 47–62. 10.4137/cgm.s21215
166
SmitM. J.VerdijkP.van der Raaij-HelmerE. M. H.NavisM.HensbergenP. J.LeursR.et al. (2003). CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C–dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood102, 1959–1965. 10.1182/blood-2002-12-3945
167
SongH.HanY.PanC.DengX.DaiW.HuL.et al. (2015). Activation of adenosine monophosphate-activated protein kinase suppresses neuroinflammation and ameliorates bone cancer pain: involvement of inhibition on mitogen-activated protein kinase. Anesthesiology123, 1170–1185. 10.1097/ALN.0000000000000856
168
SongZ. P.XiongB. R.GuanX. H.CaoF.ManyandeA.ZhouY. Q.et al. (2016). Minocycline attenuates bone cancer pain in rats by inhibiting NF-kappaB in spinal astrocytes. Acta Pharmacol. Sin.37, 753–762. 10.1038/aps.2016.1
169
SorgeR. E.MapplebeckJ. C. S.RosenS.BeggsS.TavesS.AlexanderJ. K.et al. (2015). Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat. Neurosci.18, 1081–1083. 10.1038/nn.4053
170
SorgeR. E.MartinL. J.IsbesterK. A.SotocinalS. G.RosenS.TuttleA. H.et al. (2014). Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat. Methods11, 629–632. 10.1038/nmeth.2935
171
SrokaJ.KreciochI.ZimolagE.LasotaS.RakM.Kedracka-KrokS.et al. (2016). Lamellipodia and membrane blebs drive efficient electrotactic migration of rat Walker carcinosarcoma cells WC 256. PLoS ONE11:e0149133. 10.1371/journal.pone.0149133
172
TachéY.MillionM. (2015). Role of corticotropin-releasing factor signaling in stress-related alterations of colonic motility and hyperalgesia. J. Neurogastroenterol. Motil.21, 8–24. 10.5056/jnm14162
173
TonetoA. T.Ferreira RamosL. A.SalomãoE. M.TomasinR.AereasM. A.Gomes-MarcondesM. C. (2016). Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia Sarcopenia Muscle. [Epub ahead of print]. 10.1002/jcsm.12100
174
TongW.WangW.HuangJ.RenN.WuS. X.LiY. Q. (2010). Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain. Biochem. Biophys. Res. Commun.395, 572–576. 10.1016/j.bbrc.2010.04.086
175
TrashkovA. P.Vasil'evA. G.KovalenkoA. L.PetrovA. Y.ValeevV. V. (2016). [Influence of angioprotector drugs on the efficacy of cytostatic therapy (experimental study)]. Eksp. Klin. Farmakol.79, 34–39.
176
TuttleA. H.TohyamaS.RamsayT.KimmelmanJ.SchweinhardtP.BennettG. J.et al. (2015). Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain156, 2616–2626. 10.1097/j.pain.0000000000000333
177
UrchC. (2004). The pathophysiology of cancer-induced bone pain: current understanding. Palliat. Med.18, 267–274. 10.1191/0269216304pm887ra
178
VaccaV.MarinelliS.PieroniL.UrbaniA.LuvisettoS.PavoneF. (2014). Higher pain perception and lack of recovery from neuropathic pain in females: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. Pain155, 388–402. 10.1016/j.pain.2013.10.027
179
VaccaV.MarinelliS.PieroniL.UrbaniA.LuvisettoS.PavoneF. (2016). 17beta-estradiol counteracts neuropathic pain: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. Sci. Rep.6:18980. 10.1038/srep18980
180
WalkerK.FoxA. J.UrbanL. A. (1999). Animal models for pain research. Mol. Med. Today5, 319–321. 10.1016/S1357-4310(99)01493-8
181
WalpoleA. L. (1951). The Walker carcinoma 256 in the screening of tumour inhibitors. Br. J. Pharmacol. Chemother.6, 135–143. 10.1111/j.1476-5381.1951.tb00629.x
182
WangJ.ZhangR.DongC.JiaoL.XuL.LiuJ.et al. (2012). Topical treatment with Tong-Luo-San-Jie gel alleviates bone cancer pain in rats. J. Ethnopharmacol.143, 905–913. 10.1016/j.jep.2012.08.026
183
WangJ.ZhangR.DongC.JiaoL.XuL.LiuJ.et al. (2015). Transient receptor potential channel and interleukin-17A involvement in LTTL gel inhibition of bone cancer pain in a rat model. Integr. Cancer Ther.14, 381–393. 10.1177/1534735415580677
184
WangL. N.YangJ. P.JiF. H.ZhanY.JinX. H.XuQ. N.et al. (2012a). Brain-derived neurotrophic factor modulates N-methyl-D-aspartate receptor activation in a rat model of cancer-induced bone pain. J. Neurosci. Res.90, 1249–1260. 10.1002/jnr.22815
185
WangL. N.YangJ. P.ZhanY.JiF. H.WangX. Y.ZuoJ. L.et al. (2012b). Minocycline-induced reduction of brain-derived neurotrophic factor expression in relation to cancer-induced bone pain in rats. J. Neurosci. Res.90, 672–681. 10.1002/jnr.22788
186
WangL. N.YaoM.YangJ. P.PengJ.PengY.LiC. F.et al. (2011). Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord. Mol. Pain7:48. 10.1186/1744-8069-7-48
187
WangX. W.HuS.Mao-YingQ. L.LiQ.YangC. J.ZhangH.et al. (2012a). Activation of c-jun N-terminal kinase in spinal cord contributes to breast cancer induced bone pain in rats. Mol. Brain5:21. 10.1186/1756-6606-5-21
188
WangX. W.LiT. T.ZhaoJ.Mao-YingQ. L.ZhangH.HuS.et al. (2012b). Extracellular signal-regulated kinase activation in spinal astrocytes and microglia contributes to cancer-induced bone pain in rats. Neuroscience217, 172–181. 10.1016/j.neuroscience.2012.04.065
189
WangZ. L.DuT. T.ZhangR. G. (2016). JNK in spinal cord facilitates bone cancer pain in rats through modulation of CXCL1. J. Huazhong Univ. Sci. Technol. Med. Sci.36, 88–94. 10.1007/s11596-016-1547-1
190
WebbT. E.SimonJ.BatesonA. N.BarnardE. A. (1994). Transient expression of the recombinant chick brain P2y1 purinoceptor and localization of the corresponding mRNA. Cell. Mol. Biol. (Noisy-le-grand).40, 437–442.
191
Wiesenfeld-HallinZ. (2005). Sex differences in pain perception. Gend. Med.2, 137–145. 10.1016/S1550-8579(05)80042-7
192
WilsonS. G.MogilJ. S. (2001). Measuring pain in the (knockout) mouse: big challenges in a small mammal. Behav. Brain Res.125, 65–73. 10.1016/S0166-4328(01)00281-9
193
WuJ. X.XuM. Y.MiaoX. R.LuZ. J.YuanX. M.LiX. Q.et al. (2012). Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. Eur. J. Pain16, 1378–1388. 10.1002/j.1532-2149.2012.00149.x
194
WuJ. X.YuanX. M.WangQ.WeiW.XuM. Y. (2016). Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats. Mol. Pain12:1744806916644929. 10.1177/1744806916644929
195
WuM.LuL.ZhangQ.GuoQ.ZhaoF.LiT.et al. (2016). Relating doses of contrast agent administered to tic and semi-quantitative parameters on DCE-MRI: based on a murine breast tumor model. PLoS ONE11:e0149279. 10.1371/journal.pone.0149279
196
XiaH.ZhangD.YangS.WangY.XuL.WuJ.et al. (2014). Role of ATP-sensitive potassium channels in modulating nociception in rat model of bone cancer pain. Brain Res.1554, 29–35. 10.1016/j.brainres.2014.01.032
197
XuJ.-Y.JiangY.LiuW.HuangY.-G. (2015). Calpain inhibitor reduces cancer-induced bone pain possibly through inhibition of osteoclastogenesis in rat cancer-induced bone pain model. Chin. Med. J. (Engl).128, 1102–1107. 10.4103/0366-6999.155109
198
XuQ.ZhangX. M.DuanK. Z.GuX. Y.HanM.LiuB. L.et al. (2013). Peripheral TGF-beta1 signaling is a critical event in bone cancer-induced hyperalgesia in rodents. J. Neurosci.33, 19099–19111. 10.1523/JNEUROSCI.4852-12.2013
199
YalovenkoT. M.TodorI. M.LukianovaN. Y.ChekhunV. F. (2016). Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. Exp. Oncol.38, 84–88.
200
YangY.LiH.LiT. T.LuoH.GuX. Y.LüN.et al. (2015). Delayed activation of spinal microglia contributes to the maintenance of bone cancer pain in female Wistar rats via P2X7 receptor and IL-18. J. Neurosci.35, 7950–7963. 10.1523/JNEUROSCI.5250-14.2015
201
YaoM.YangJ. P.WangL. N.ChengH.ZhangY. B.XuQ. N.et al. (2008). [Feasibility of establishment of rat model of bone cancer pain by using Walker 256 cells cultured in vitro or in vivo]. Zhonghua Yi Xue Za Zhi88, 880–884.
202
YaoP.DingY.WangZ.MaJ.HongT.ZhuY.et al. (2016). Impacts of anti-nerve growth factor antibody on pain-related behaviors and expressions of opioid receptor in spinal dorsal horn and dorsal root ganglia of rats with cancer-induced bone pain. Mol. Pain12:1744806916644928. 10.1177/1744806916644928
203
YeD.BuH.GuoG.ShuB.WangW.GuanX.et al. (2014). Activation of CXCL10/CXCR3 signaling attenuates morphine analgesia: involvement of Gi protein. J. Mol. Neurosci.53, 571–579. 10.1007/s12031-013-0223-1
204
YinQ.ChengW.ChengM. Y.FanS. Z.ShenW. (2010). Intrathecal injection of anti-CX3CR1 neutralizing antibody delayed and attenuated pain facilitation in rat tibial bone cancer pain model. Behav. Pharmacol.21, 595–601. 10.1097/FBP.0b013e32833e7e2a
205
YuS.PengH. D.JuD. W.WeiP. K.XuL.LaoL. X.et al. (2009). Mechanisms of treatment of cancer pain with a topical Chinese herbal formula in rats. Chin. Med. J.122, 2027–2031.
206
YungY. C.StoddardN. C.ChunJ. (2014). LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res.55, 1192–1214. 10.1194/jlr.R046458
207
ZhangJ. Y.GongN.HuangJ. L.GuoL. C.WangY. X. (2013). Gelsemine, a principal alkaloid from Gelsemium sempervirens Ait., exhibits potent and specific antinociception in chronic pain by acting at spinal alpha3 glycine receptors. Pain154, 2452–2462. 10.1155/2015/752512
208
ZhangM. Y.LiuY. P.ZhangL. Y.YueD. M.QiD. Y.LiuG. J.et al. (2015). Levo-tetrahydropalmatine attenuates bone cancer pain by inhibiting microglial cells activation. Mediators Inflamm.2015:752512. 10.1155/2015/752512
209
ZhaoJ.PanH. L.LiT. T.ZhangY. Q.WeiJ. Y.ZhaoZ. Q. (2010). The sensitization of peripheral C-fibers to lysophosphatidic acid in bone cancer pain. Life Sci.87, 120–125. 10.1016/j.lfs.2010.05.015
210
ZhaoQ.ZhangL.ShuR.WangC.YuY.WangH.et al. (2016). Involvement of spinal PKMzeta expression and phosphorylation in remifentanil-induced long-term hyperalgesia in rats. Cell. Mol. Neurobiol.. [Epub ahead of print]. 10.1007/s10571-016-0401-0
211
ZhaoY.TianL.ShengW.MiaoJ.YangJ. (2013). Hypalgesia effect of IL-24, a quite new mechanism for IL-24 application in cancer treatment. J. Interferon Cytokine Res.33, 606–611. 10.1089/jir.2012.0146
212
ZhouY. L.JiangG. Q.WeiJ.ZhangH. H.ChenW.ZhuH.et al. (2015). Enhanced binding capability of nuclear factor-kappaB with demethylated P2X3 receptor gene contributes to cancer pain in rats. Pain156, 1892–1905. 10.1097/j.pain.0000000000000248
213
ZhuB.GongN.FanH.PengC. S.DingX. J.JiangY.et al. (2014). Lamiophlomis rotata, an orally available Tibetan herbal painkiller, specifically reduces pain hypersensitivity states through the activation of spinal glucagon-like peptide-1 receptors. Anesthesiology121, 835–851. 10.1097/aln.0000000000000320
214
ZhuG.DongY.HeX.ZhaoP.YangA.ZhouR.et al. (2016). Radiotherapy suppresses bone cancer pain through inhibiting activation of camp signaling in rat dorsal root ganglion and spinal cord. Mediators Inflamm.2016:5093095. 10.1155/2016/5093095
215
ZhuG. Q.LiuS.HeD. D.LiuY. P.SongX. J. (2014). Activation of the cAMP-PKA signaling pathway in rat dorsal root ganglion and spinal cord contributes toward induction and maintenance of bone cancer pain. Behav. Pharmacol.25, 267–276. 10.1097/fbp.0000000000000048
216
ZhuS.WangC.HanY.SongC.HuX.LiuY. (2015). Sigma-1 receptor antagonist bd1047 reduces mechanical allodynia in a rat model of bone cancer pain through the inhibition of spinal nr1 phosphorylation and microglia activation. Mediators Inflamm.2015, 4239–4245. 10.1155/2015/265056
Summary
Keywords
breast cancer, metastasis, bone pain, Walker 256 cell, rat model
Citation
Shenoy PA, Kuo A, Vetter I and Smith MT (2016) The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. Front. Pharmacol. 7:286. doi: 10.3389/fphar.2016.00286
Received
22 June 2016
Accepted
18 August 2016
Published
31 August 2016
Volume
7 - 2016
Edited by
Ajay Sharma, Chapman University, USA
Reviewed by
Guilherme Lucas, University of São Paulo, Brazil; Dan Cacsire Castillo-Tong, Medical University of Vienna, Austria; Roberto Jose Fajardo, University of Texas Health Science Center at San Antonio, USA
Updates
Copyright
© 2016 Shenoy, Kuo, Vetter and Smith.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maree T. Smith maree.smith@uq.edu.au
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.